Ipamorelin

Selective growth hormone secretagogue (GHRP) with minimal effect on cortisol or prolactin.

Quick Reference

Dose: 100–300 mcg per injection
Frequency / schedule: 1–3× daily
Route: Subcutaneous
Timing: Fasted windows — especially pre-bed
Fasting: Empty stomach required (at least 1–2 hours after food)
Cycle: 8–12 weeks
Time off: 4 weeks off
Common vial strengths: 2 mg, 5 mg, 10 mg

How this works

Ipamorelin is a selective ghrelin-mimetic that binds the growth hormone secretagogue receptor (GHS-R / GHSR). It triggers a clean pulse of GH release from the pituitary with very little stimulation of ACTH, cortisol, or prolactin — making it one of the cleanest GHRPs available. It is almost always stacked with a GHRH analog (CJC-1295 no-DAC or Sermorelin) for synergistic effect.

Benefits + side effects

Potential Benefits

Clean GH pulse
Supports recovery and sleep quality
Minimal unwanted hormonal side effects compared with older GHRPs

Side Effects

Mild injection-site reactions
Occasional hunger or vivid dreams
Water retention (usually mild)

Dosing / Protocol

Reference Protocol

Phase / week	Dose	Frequency	Timing	Notes
Standard	100–200 mcg	1–3× daily	Fasted (AM / post-workout / pre-bed)	Pre-bed is most important
Higher	200–300 mcg	2–3× daily	Same	If well tolerated

Timing + Fasting Notes

Must be injected on an empty stomach. Ideal windows: upon waking (fasted), post-workout (if fasted), and especially 30–60 minutes before bed. Food (particularly carbohydrates) strongly blunts the GH pulse.

Reconstitution

Common vial strengths2 mg, 5 mg, 10 mg

Approved preparation example
5 mg + 2 mL BAC → 2.5 mg/mL (100 mcg = 4 units)

Practical Reference

Storage: Lyophilized frozen/refrigerated; reconstituted refrigerated, use within 28 days
Route / injection context: Subcutaneous
Bloodwork / markers: IGF-1
Common vial strengths: 2 mg, 5 mg, 10 mg
Cycle / time off: 8–12 weeks · 4 weeks off
Practical notes: Almost always stacked with a GHRH analog. Research use only.

References

Ipamorelin, the first selective growth hormone secretagogueEuropean Journal of Endocrinology · 1998

PRECLINICAL

THE SIGNAL · SENT TWICE A MONTH

Stay ahead of the research without living on PubMed.

Peptide references, research worth knowing, new FEMETRIC tools, and meaningful testing updates. Twice a month. No daily emails.By subscribing, you agree to receive The Signal from FEMETRIC. Unsubscribe anytime.

Search Femetric